Skip to content
DataLookout
Menu

NCT07512271

Generative AI Patient Education Module for Breast Oncology

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  2. Notable Recruitment opened
    • Start date changed from estimate of Aug 15, 2026 to Jul 14, 2026
    • Site details revised
    v3
  3. Notable Start date: May 1, 2026 to Aug 15, 2026
    • Primary and study completion pushed from Dec 31, 2026 to Jan 31, 2027
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Mean score of Safety and Risk Assessment (Lead-in and Provider)
Timeframe: Up to 90 months
Mean score of Provider Assessment of AI patient Education Tool Survey (Provider)
Timeframe: Up to 180 days
Mean score of Assessment of Answer Accuracy and Content Appropriateness (Provider)
Timeframe: Uup to 180 days

Secondary (4)

Mean score of AI Tool Experience survey (Participant)
Mean score of Medical Information Experience Survey (Participant)
Mean Change of Score of Patient AI Tool Experience Survey (Participant)
Mean Change of Score of Medical Information Experience Survey (Participant)

Arms and interventions

Safety Lead-in PhaseExperimental

Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.

Interventional (Immediate Access)Experimental

Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.

Control (Delayed Access)Experimental

Participants will be given access to OpenEvidence CareConnect for 3 months 90 days after enrollment

Other: Survey (Participant), OpenEvidence CareConnect, Survey (Provider)

Sites

1 site in 1 country

  • University of California, San FranciscoSan Francisco, California, United States